Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 5/2015

01-05-2015 | Original Article - Clinical Oncology

Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation

Authors: Claudia Seifert, Susan Wittig, Clemens Arndt, Bernd Gruhn

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2015

Login to get access

Abstract

Purpose

Sinusoidal obstruction syndrome (SOS) is a life-threatening early complication after hematopoietic stem cell transplantation (HSCT), and until now, examinations about the influence of genetic risk factors are extremely rare. The purpose of this study was to identify an association between heparanase (HPSE) single nucleotide polymorphisms (SNPs) and SOS in children undergoing allogeneic HSCT.

Methods

We retrospectively analyzed the distribution of the both HPSE SNPs rs4693608 and rs4364254 and the occurrence of SOS after allogeneic HSCT in 160 children with malignant and non-malignant diseases.

Results

Patients with HPSE genotypes GG or AG of rs4693608 (G>A) had a significantly reduced incidence of SOS on day 100 after HSCT compared to patients with genotype AA (4.7 vs. 14.3 %, P = 0.038). In addition, incidence of SOS in patients with genotype CC or CT of rs4364254 (C>T) was significantly decreased in comparison with patients with genotype TT (2.3 vs. 14.7 %, P = 0.004). Interestingly, no patient with genotype CC developed SOS. Because both SNPs co-occur in vivo, we generated subsets: AA–TT, GG–CC, and a group with remaining SNP combinations. We found significant differences between all three patient groups (P = 0.035). Patients with AA–TT showed the highest incidence of SOS (16.7 %), while SOS did not appear in patients with GG–CC (0 %) and residual combinations were numerically in-between (4.9 %). An impact caused by main patient and donor characteristics, established risk factors for SOS, and conditioning regimen could be excluded in multivariate analyses.

Conclusions

HPSE polymorphisms turned out to be significant independent risk factors (P = 0.030) for development of SOS and should be evaluated in further trials.
Literature
go back to reference Barker CC, Butzner JD, Anderson RA, Brant R, Sauve RS (2003) Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients. Bone Marrow Transpl 32(1):79–87CrossRef Barker CC, Butzner JD, Anderson RA, Brant R, Sauve RS (2003) Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients. Bone Marrow Transpl 32(1):79–87CrossRef
go back to reference Benimetskaya I, Wu S, Voskresensky AM, Echart C, Zhou JF, Shin J et al (2008) Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 112(10):4343–4352CrossRefPubMed Benimetskaya I, Wu S, Voskresensky AM, Echart C, Zhou JF, Shin J et al (2008) Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 112(10):4343–4352CrossRefPubMed
go back to reference Bulley SR, Strahm B, Doyle J, Dupuis LL (2007) Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer 48(7):700–704CrossRefPubMed Bulley SR, Strahm B, Doyle J, Dupuis LL (2007) Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer 48(7):700–704CrossRefPubMed
go back to reference Carreras E, Díaz-Beyá M, Rosiñol L, Martínez C, Fernández-Avilés F, Rovira M (2011) The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transpl 17(11):1713–1720CrossRef Carreras E, Díaz-Beyá M, Rosiñol L, Martínez C, Fernández-Avilés F, Rovira M (2011) The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transpl 17(11):1713–1720CrossRef
go back to reference Chalandon Y, Roosnek E, Mermillod B, Newton A, Ozsahin H, Wacker P et al (2004) Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transpl 10(5):347–354CrossRef Chalandon Y, Roosnek E, Mermillod B, Newton A, Ozsahin H, Wacker P et al (2004) Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transpl 10(5):347–354CrossRef
go back to reference Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C et al (2000) Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 111(4):1122–1129CrossRefPubMed Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C et al (2000) Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 111(4):1122–1129CrossRefPubMed
go back to reference Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A et al (2010) Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl 16(2):157–168CrossRef Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A et al (2010) Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl 16(2):157–168CrossRef
go back to reference Corbacioglu S, Hönig M, Lahr G, Stöhr S, Berry G, Friedrich W et al (2006) Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transpl 38(8):547–553CrossRef Corbacioglu S, Hönig M, Lahr G, Stöhr S, Berry G, Friedrich W et al (2006) Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transpl 38(8):547–553CrossRef
go back to reference Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A et al (2012) Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 379(9823):1301–1309CrossRefPubMed Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A et al (2012) Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 379(9823):1301–1309CrossRefPubMed
go back to reference Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A et al (2013) BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 163(4):444–457CrossRefPubMed Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A et al (2013) BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 163(4):444–457CrossRefPubMed
go back to reference Elbahlawan L, McArthur J, Quasney MW, Pei D, Srivastava K, Dahmer MK et al (2012) Association of IL-1β-511 polymorphism with severe veno-occlusive disease in pediatric-matched allogeneic hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 34(3):175–179CrossRefPubMed Elbahlawan L, McArthur J, Quasney MW, Pei D, Srivastava K, Dahmer MK et al (2012) Association of IL-1β-511 polymorphism with severe veno-occlusive disease in pediatric-matched allogeneic hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 34(3):175–179CrossRefPubMed
go back to reference Fine JP, Gray RJ (1999) A proportional hazards model for the sub-distribution of a competing risk. JASA 94:496–509CrossRef Fine JP, Gray RJ (1999) A proportional hazards model for the sub-distribution of a competing risk. JASA 94:496–509CrossRef
go back to reference Guglielmelli T, Bringhen S, Palumbo A (2012) Update on the use of defibrotide. Expert Opin Biol Ther 12(3):353–361CrossRefPubMed Guglielmelli T, Bringhen S, Palumbo A (2012) Update on the use of defibrotide. Expert Opin Biol Ther 12(3):353–361CrossRefPubMed
go back to reference Hasegawa S, Horibe K, Kawabe T, Kato K, Kojima S, Matsuyama T, Hirabayashi N (1998) Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Bone Marrow Transpl 22(12):1191–1197CrossRef Hasegawa S, Horibe K, Kawabe T, Kato K, Kojima S, Matsuyama T, Hirabayashi N (1998) Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Bone Marrow Transpl 22(12):1191–1197CrossRef
go back to reference Ho VT, Revta C, Richardson PG (2008) Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transpl 41(3):229–237CrossRef Ho VT, Revta C, Richardson PG (2008) Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transpl 41(3):229–237CrossRef
go back to reference Lee SH, Yoo KH, Sung KW, Koo HH, Kwon YJ, Kwon MM et al (2010) Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Bone Marrow Transpl 45(8):1287–1293CrossRef Lee SH, Yoo KH, Sung KW, Koo HH, Kwon YJ, Kwon MM et al (2010) Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Bone Marrow Transpl 45(8):1287–1293CrossRef
go back to reference Lennard L, Richards S, Cartwright CS, Mitchell C, Lilleyman JS, Vora A et al (2006) The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 80(4):375–383CrossRefPubMed Lennard L, Richards S, Cartwright CS, Mitchell C, Lilleyman JS, Vora A et al (2006) The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 80(4):375–383CrossRefPubMed
go back to reference Maradei SC, Maiolino A, de Azevedo AM, Colares M, Bouzas LF, Nucci M (2009) Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 114(6):1270–1275CrossRefPubMed Maradei SC, Maiolino A, de Azevedo AM, Colares M, Bouzas LF, Nucci M (2009) Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 114(6):1270–1275CrossRefPubMed
go back to reference McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM et al (2007) Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 31(5):599–604CrossRefPubMed McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM et al (2007) Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 31(5):599–604CrossRefPubMed
go back to reference Mitsiades CS, Rouleau C, Echart C, Menon K, Teicher B, Distaso M et al (2009) Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res 15(4):1210–1221CrossRefPubMed Mitsiades CS, Rouleau C, Echart C, Menon K, Teicher B, Distaso M et al (2009) Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res 15(4):1210–1221CrossRefPubMed
go back to reference Morabito F, Gentile M, Gay F, Bringhen S, Mazzone C, Vigna E et al (2009) Insights into defibrotide: an updated review. Expert Opin Biol Ther 9(6):763–772CrossRefPubMed Morabito F, Gentile M, Gay F, Bringhen S, Mazzone C, Vigna E et al (2009) Insights into defibrotide: an updated review. Expert Opin Biol Ther 9(6):763–772CrossRefPubMed
go back to reference Ostrovsky O, Korostishevsky M, Levite I, Leiba M, Galski H, Vlodavsky I et al (2007) Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. Leukemia 21(11):2296–2303CrossRefPubMed Ostrovsky O, Korostishevsky M, Levite I, Leiba M, Galski H, Vlodavsky I et al (2007) Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. Leukemia 21(11):2296–2303CrossRefPubMed
go back to reference Ostrovsky O, Korostishevsky M, Shafat I, Mayorov M, Ilan N, Vlodavsky I et al (2009) Inverse correlation between HPSE gene single nucleotide polymorphisms and heparanase expression: possibility of multiple levels of heparanase regulation. J Leukoc Biol 86(2):445–455CrossRefPubMedCentralPubMed Ostrovsky O, Korostishevsky M, Shafat I, Mayorov M, Ilan N, Vlodavsky I et al (2009) Inverse correlation between HPSE gene single nucleotide polymorphisms and heparanase expression: possibility of multiple levels of heparanase regulation. J Leukoc Biol 86(2):445–455CrossRefPubMedCentralPubMed
go back to reference Ostrovsky O, Shimoni A, Rand A, Vlodavsky I, Nagler A (2010) Genetic variations in the heparanase gene (HPSE) associate with increased risk of GvHD following allogenic stem cell transplantation: effect of discrepancy between recipients and donors. Blood 115(11):2319–2328CrossRefPubMedCentralPubMed Ostrovsky O, Shimoni A, Rand A, Vlodavsky I, Nagler A (2010) Genetic variations in the heparanase gene (HPSE) associate with increased risk of GvHD following allogenic stem cell transplantation: effect of discrepancy between recipients and donors. Blood 115(11):2319–2328CrossRefPubMedCentralPubMed
go back to reference Ouachée-Chardin M, Elie C, de Saint Basile G, Le Deist F, Mahlaoui N, Picard C et al (2006) Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics 117(4):e743–e750CrossRefPubMed Ouachée-Chardin M, Elie C, de Saint Basile G, Le Deist F, Mahlaoui N, Picard C et al (2006) Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics 117(4):e743–e750CrossRefPubMed
go back to reference Pihusch R, Salat C, Schmidt E, Göhring P, Pihusch M, Hiller E et al (2002) Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 74(9):1303–1309CrossRefPubMed Pihusch R, Salat C, Schmidt E, Göhring P, Pihusch M, Hiller E et al (2002) Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 74(9):1303–1309CrossRefPubMed
go back to reference Platzbecker U, Bornhäuser M (2012) SOS for veno-occlusive disease: defibrotide prophylaxis. Lancet 379(9823):1277–1278CrossRefPubMed Platzbecker U, Bornhäuser M (2012) SOS for veno-occlusive disease: defibrotide prophylaxis. Lancet 379(9823):1277–1278CrossRefPubMed
go back to reference Qureshi A, Marshall L, Lancaster D (2008) Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer 50(4):831–832CrossRefPubMed Qureshi A, Marshall L, Lancaster D (2008) Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer 50(4):831–832CrossRefPubMed
go back to reference Richardson P, Bearman SI (1998) Prevention and treatment of hepatic venoocclusive disease after high-dose cytoreductive therapy. Leuk Lymphoma 31(3–4):267–277PubMed Richardson P, Bearman SI (1998) Prevention and treatment of hepatic venoocclusive disease after high-dose cytoreductive therapy. Leuk Lymphoma 31(3–4):267–277PubMed
go back to reference Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D et al (2002) Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 100(13):4337–4343CrossRefPubMed Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D et al (2002) Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 100(13):4337–4343CrossRefPubMed
go back to reference Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J et al (2010) Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transpl 16(7):1005–1017CrossRef Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J et al (2010) Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transpl 16(7):1005–1017CrossRef
go back to reference Ringdén O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindeløv L et al (1994) A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies. Transpl Proc 26(3):1831–1832 Ringdén O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindeløv L et al (1994) A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies. Transpl Proc 26(3):1831–1832
go back to reference Rocha V, Porcher R, Fernandes JF, Filion A, Bittencourt H, Silva W Jr et al (2009) Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 23(3):545–556CrossRefPubMed Rocha V, Porcher R, Fernandes JF, Filion A, Bittencourt H, Silva W Jr et al (2009) Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 23(3):545–556CrossRefPubMed
go back to reference Toh HC, McAfee SL, Sackstein R, Cox BF, Colby C, Spitzer TR (1999) Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transpl 24(8):891–895CrossRef Toh HC, McAfee SL, Sackstein R, Cox BF, Colby C, Spitzer TR (1999) Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transpl 24(8):891–895CrossRef
Metadata
Title
Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation
Authors
Claudia Seifert
Susan Wittig
Clemens Arndt
Bernd Gruhn
Publication date
01-05-2015
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 5/2015
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1857-2

Other articles of this Issue 5/2015

Journal of Cancer Research and Clinical Oncology 5/2015 Go to the issue